Ocular Therapeutix (NASDAQ:OCUL) Trading 8.8% Higher Following Better-Than-Expected Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares were up 8.8% on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $10.08 and last traded at $9.30. Approximately 3,420,981 shares changed hands during trading, a decline of 34% from the average daily volume of 5,198,589 shares. The stock had previously closed at $8.55.

The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.05. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. The business had revenue of $13.25 million for the quarter. During the same period last year, the company earned ($0.29) earnings per share. The business’s revenue for the quarter was down 22.4% compared to the same quarter last year.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Q4 EPS beat — Ocular reported GAAP EPS of ($0.29) vs. consensus ($0.34), a small beat that can be read as a modest near‑term positive on profitability trajectory and helped limit downside. Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
• Positive Sentiment: Analyst support remains – multiple firms continue buy/outperform ratings and the consensus price target sits well above current levels, providing potential upside if clinical/readout news is favorable. Ocular Therapeutix Stock Page
• Neutral Sentiment: Company released its full Q4 and FY2025 financial results and business highlights; the report gives more detail on revenue drivers, pipeline timelines and cash position that investors will parse ahead of the pivotal readout. Ocular Therapeutix: Q4 Earnings Snapshot
• Negative Sentiment: Revenue miss and year‑over‑year decline — Q4 revenue of $13.25M was down ~22% YoY and missed some estimates, a clear negative for near‑term growth expectations. Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates
• Negative Sentiment: Rival publicity ahead of readout — Eyepoint Pharmaceuticals publicly challenged Ocular on the eve of a pivotal trial readout, raising competitive and perception risk that can pressure the stock ahead of binary clinical news. A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment
• Negative Sentiment: Insider selling — COO Donald Notman sold shares in early February (multiple transactions), which can be interpreted negatively by some investors even if part of routine diversification. Donald Notman Sells 5,455 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock
• Negative Sentiment: Unusual bearish options activity — traders purchased an elevated number of put options (large spike vs. average), signaling short-term bearish positioning ahead of the readout and amplifying volatility risk.

Wall Street Analysts Forecast Growth

OCUL has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $20.00 price target on shares of Ocular Therapeutix in a research note on Monday, December 8th. Wall Street Zen downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. TD Cowen reissued a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, January 22nd. Finally, HC Wainwright increased their price objective on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Insider Activity

In related news, COO Donald Notman sold 6,035 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $8.54, for a total transaction of $51,538.90. Following the sale, the chief operating officer owned 377,802 shares of the company’s stock, valued at $3,226,429.08. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ocular Therapeutix

Several hedge funds have recently modified their holdings of OCUL. Nisa Investment Advisors LLC raised its position in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,392 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Ocular Therapeutix by 17.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 893 shares during the last quarter. KBC Group NV purchased a new stake in Ocular Therapeutix in the 4th quarter worth approximately $78,000. Quarry LP acquired a new position in Ocular Therapeutix in the 3rd quarter valued at $80,000. Finally, Trust Co. of Vermont lifted its stake in shares of Ocular Therapeutix by 24.3% during the 4th quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,750 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Trading Up 4.2%

The business has a 50 day simple moving average of $11.88 and a two-hundred day simple moving average of $11.95. The company has a current ratio of 7.85, a quick ratio of 7.78 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.90 billion, a PE ratio of -6.19 and a beta of 0.90.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.